Posted by Michael Wonder on 25 Nov 2025
FDA approves durvalumab for resectable gastric or gastro-oesophageal junction adenocarcinoma
25 November 2025 - Today, the FDA approved durvalumab (Imfinzi, AstraZeneca) with fluorouracil, leucovorin, oxaliplatin, and docetaxel (FLOT) chemotherapy as neo-adjuvant and adjuvant treatment, followed by single agent durvalumab, for adults with resectable gastric or gastro-oesophageal junction adenocarcinoma.
Efficacy was evaluated in MATTERHORN, a randomised, double-blind, placebo-controlled, multi-centre trial conducted in 948 patients with previously untreated and resectable, stage II to stage IVA, gastric or gastro-oesophageal junction adenocarcinoma.
